Why the study?
The management of device-detected AF in patients with prior stroke or TIA remains a clinical dilemma, balancing stroke prevention against anticoagulant-related bleeding risks.
Do direct oral anticoagulants (edoxaban or apixaban) reduce stroke or systemic embolism without unacceptable major bleeding compared to aspirin or placebo in patients with device-detected atrial fibrillation and a history of stroke or TIA?
Systematic Review (n=599)
Do direct oral anticoagulants (edoxaban or apixaban) reduce stroke or systemic embolism without unacceptable major bleeding compared to aspirin or placebo in patients with device-detected atrial fibrillation and a history of stroke or TIA?
Answers are grounded in this paper and cite their sources.
Randomized evidence for DOACs in patients with device-detected atrial fibrillation and prior stroke or TIA is discordant—showing stroke reduction with apixaban in ARTESIA alongside higher arrhythmia burden, but neutral efficacy with edoxaban in NOAH-AFNET 6, and increased major bleeding in both—necessitating individualized risk stratification.
The management of device-detected atrial fibrillation in patients with a history of stroke or transient ischemic attack remains a clinical dilemma, balancing the potential benefits of stroke prevention against the risks of anticoagulant-related bleeding. This review synthesizes evidence from the NOAH-AFNET 6 and ARTESIA trials, which evaluated the efficacy and safety of direct oral anticoagulants in this population. Collectively, randomized evidence regarding the use of direct oral anticoagulants in patients with device-detected atrial fibrillation and a history of stroke or transient ischemic attack remains limited and internally discordant. In ARTESIA, apixaban was associated with a reduction in ischemic stroke accompanied by an increase in major bleeding, yielding a relatively coherent benefit–risk signal in this high-risk subgroup. In contrast, NOAH-AFNET 6 demonstrated a modest and statistically non-significant reduction in ischemic stroke alongside a substantial increase in major bleeding. Further research is still needed to refine patient selection and optimize therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a systematic review in Device-detected atrial fibrillation (DDAF) with a history of stroke or transient ischemic attack (TIA) (n=599). Direct oral anticoagulants (apixaban or edoxaban) vs. Placebo or aspirin was evaluated on Stroke or systemic embolism in ARTESIA prior stroke/TIA subgroup (HR 0.40, 95% CI 0.17-0.95).
Synapse has enriched 10 related papers. Consider them for comparative context: